Today the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,033,628, which is directed to methods related to the use and administration of certain PAX2 inhibitors for treating drug-resistant breast cancer. Dr. Carlton D. Donald, President and CEO of PHIGENIX, commented, “We are extremely pleased with the addition of this new patent to our portfolio to extend our cutting-edge, next-generation medical innovations. The technology covered in this patent has the potential to revolutionize how physicians determine the most effective course of treatment for breast cancer patients.“ The entire press release can be read here.